US 2023/0272015 A1 · VACCINE COMPOSITION FOR PREVENTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION

Vaccine composition for preventing severe acute respiratory syndrome coronavirus 2 infection

AssigneesGeneone Life Science, Inc., Korea Disease Control and Prevention Agency

InventorsYoung Keun Park, Byung Mun Cho, Moon Sup Jeong, Hyo Jin Lee, Song Yion Yeu, Young Ran Cho, Bo Yeong Park, Areum Gil, Bo Hyun Jeon, Ye Eun Oh, Gee Ho Park, Joel Maslow, Christine Claire Roberts, Mi Young KIM, Jung Ah Lee, Hee Ji Lim, Yun Ho Hwang

Life of this patent

Estimating the term…

Abstract

The present invention relates to a vaccine composition for preventing severe acute respiratory syndrome coronavirus 2 infection. The vaccine composition for preventing severe acute respiratory syndrome coronavirus 2 infection according to the present invention comprises spike and ORF3a or nucleocapsid as an antigen against SARS-CoV-2. The vaccine composition has a significant effect of inducing antibody immune responses and T-cell immune responses by a plurality of co-expressed antigens compared to those comprising one antigen, and thus can be variously used in the field of prevention of severe acute respiratory syndrome coronavirus 2 infection.

Claims25

Dependent claims

A method for preventing severe acute respiratory syndrome coronavirus 2 infection comprising treating a composition for preventing severe acute reparatory syndrome coronavirus 2 infection to a subject:

wherein the composition comprises (a) a SARS-CoV-2 Spike protein or a gene encoding the SARS-CoV-2 Spike protein;
and
(b) a SARS-CoV-2 ORF3a protein or a gene encoding the SARS-CoV-2 ORF3a;
or a SARS-CoV-2 nucleocapsid or a gene encoding the SARS-CoV-2 nucleocapsid.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

18/016,666Filed 19 Jul 2021

Priority

KR 102020008899217 Jul 2020

Published

31 Aug 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification16 codes

C07K 14/005
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from viruses
C07K 14/165
RNA viruses: coronaviridae, e.g. avian infectious bronchitis virus
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
A61P 31/14
Antivirals: for RNA viruses